Targeting immune cells to improve cancer treatment
In vivo efficacy, safety and PK/PD analysis of SYN101, a first in class, immune cell targeted TGFb therapy for cancer patients
['FUNDING_SBIR_2'] · SYNTHIS THERAPEUTICS, INC. · NIH-11194516
This study is testing a new treatment called SYN101 that helps your immune system fight aggressive cancers like colorectal and melanoma by blocking a harmful substance, aiming to make cancer treatments work better while reducing side effects.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SYNTHIS THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (New York City, UNITED STATES) |
| Trial ID | NIH-11194516 on ClinicalTrials.gov |
What this research studies
This research investigates a new therapy called SYN101, which specifically targets immune cells to block a harmful cytokine known as TGF-β that can hinder cancer treatment. By focusing on T cells, the therapy aims to enhance the immune response against various aggressive cancers, including colorectal and melanoma. The approach seeks to minimize side effects commonly associated with traditional TGF-β therapies, which can be toxic to the heart and may worsen some tumors. Patients participating in this research may receive a treatment designed to improve their chances of responding to existing cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced cancers that have shown resistance to current immune checkpoint inhibitors.
Not a fit: Patients with early-stage cancers or those who do not have elevated levels of TGF-β may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes for cancer patients by enhancing the effectiveness of existing therapies.
How similar studies have performed: Previous research has shown promise in targeting TGF-β in cancer therapies, but this specific approach focusing on immune cells is relatively novel.
Where this research is happening
New York City, UNITED STATES
- SYNTHIS THERAPEUTICS, INC. — New York City, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: THOMAS-KARYAT, DORI A — SYNTHIS THERAPEUTICS, INC.
- Study coordinator: THOMAS-KARYAT, DORI A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, anti-cancer therapy